TY  - JOUR

T1  - VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer.

JO  - Journal of Clinical Oncology

PY  - 2018/05/20

AU  - Redchenko I

AU  - Cappuccini F

AU  - Pollock E

AU  - Bryant RJ

AU  - Carter L

AU  - Verrill C

AU  - Hollidge J

AU  - Goodwin L

AU  - Harrop R

AU  - Romero PJ

AU  - Vigano S et al

ED  - 

DO  - DOI: 10.1200/jco.2018.36.15_suppl.3018

PB  - American Society of Clinical Oncology (ASCO)

VL  - 36

IS  - 15_suppl

SP  - 3018

EP  - 3018

Y2  - 2024/10/23

ER  -